Bayer submits marketing authorization application for BAY94-9027 for the treatment of Hemophilia A in the EU (for specialized target groups only)

Pivotal studies with BAY94-9027 showed that bleed protection was achieved with extended dosing intervals
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news